To gain a comprehensive understanding about the expression of ZFP36L1 in MIBC tumors of different clinicopathological features, we then investigated the relationships between ZFP36L1 expressing levels and clinicopathological parameters in the TCGA-BLCA patients. This evidence concerns the gene ZFP36L1 and bladder transitional cell carcinoma.